Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity.

British journal of haematology - 1 May 2020

Onecha Esther, Ruiz-Heredia Yanira, Martínez-Cuadrón David, Barragán Eva, Martinez-Sanchez Pilar, Linares María, Rapado Inmaculada, Perez-Oteyza Jaime, Magro Elena, Herrera Pilar, Rojas José Luis, Gorrochategui Julián, Villoria Jesús, Boluda Blanca, Sargas Claudia, Ballesteros Joan, Montesinos Pau, Martínez-López Joaquín, Ayala Rosa

Abstract excerpt

Refractoriness to induction therapy and relapse after complete remission are the leading causes of death in patients with acute myeloid leukaemia (AML). This study focussed on the prediction of response to standard induction therapy and outcome of patients with AML using a combined strategy of mutational profiling by next-generation sequencing (NGS, n = 190) and ex vivo PharmaFlow testing (n = 74) for the 10 most...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Cohort Studies

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Treatment Outcome

Share to Young Adult

Source

Identifiers

PMID: 32068246
DOI: 10.1111/bjh.16432

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity.PMID 32068246Read ↗

Integrating ex vivo drug sensitivity and genetic mutation analysis improves prediction of chemotherapy response in acute myeloid leukemia.Semantic proximity Read ↗

Clinical Forecasting using <i>Ex Vivo</i> Drug Sensitivity Profiling of Acute Myeloid LeukemiaSemantic proximity Read ↗

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group.Semantic proximity Read ↗

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.Semantic proximity Read ↗

Mutation Patterns Predict Drug Sensitivity in Acute Myeloid LeukemiaSemantic proximity Read ↗

Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.Semantic proximity Read ↗

Machine Learning for Predicting Therapeutic Outcomes in Acute Myeloid Leukemia PatientsSemantic proximity Read ↗

Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors.Semantic proximity Read ↗

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.Semantic proximity Read ↗

Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study.Semantic proximity Read ↗

Cytogenetic and Molecular Genetic Driven Prediction of Response to First-Treatment and Prognosis in Acute Myeloid Leukemia: A Retrospective Cohort Study.Semantic proximity Read ↗

Real-world genomic profiling of acute myeloid leukemia and the impact of European LeukemiaNet risk stratification 2022 update.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.